Login
$KARX
$0.16 +$0.00 (0.06%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2027
As of Aug 31, 2026
Q4 FY2026
As of May 31, 2026
Q3 FY2026
As of Feb 28, 2026
Q2 FY2026
As of Nov 30, 2025
Q1 FY2026
As of Aug 31, 2025
Q3 FY2025
As of Feb 28, 2025
Q2 FY2025
As of Nov 30, 2024
Q1 FY2025
As of Aug 31, 2024
Q4 FY2024
As of May 31, 2024
Q3 FY2024
As of Feb 29, 2024
Q1 FY2024
As of Aug 31, 2023
Q4 FY2023
As of May 31, 2023
Q2 FY2023
As of Nov 30, 2022
Q1 FY2023
As of Aug 31, 2022
Q4 FY2022
As of May 31, 2022
Q3 FY2022
As of Feb 28, 2022
Q2 FY2022
As of Nov 30, 2021
Q1 FY2022
As of Aug 31, 2021
Q4 FY2021
As of May 31, 2021
Current assets
Cash
Cash and cash equivalents
Accounts receivable, net
Inventories, net
Investment in Silviculture
Loan receivable, net of allowance of $628,196
Deposits
Loan receivable, net of allowance of $1,117,470 and $628,196
Convertible note receivable - related party (Note 21)
Prepaid expenses
Investments in equity securities
Securities receivable
Other current assets
Securities receivables
Total current assets
Property, plant and equipment, net
Property and equipment, net
Right of use asset, net
Security deposit
Capitalized App Development Costs, Net
Contract fulfillment assets
Other assets
Internally developed software, net
Intangible assets, net
Total assets
Current liabilities
Accounts payable
Deferred revenues
Short term loan payable
Deferred revenue
Credit Card
Due from related Parties
Stock payable
Related party loan
Convertible notes payable, net of discounts
Convertible notes - interest payable
Embedded derivative
Derivative liabilities
Current portion of lease liabilities
Receivables financing obligations
Term loan payable
Other current liabilities
Payroll liabilities
Total current liabilities
Long-term debt
Long term convertible notes payable
Non-current portion of lease liabilities
Other liabilities
Convertible notes payable, non-current
Total liabilities
Commitments and contingencies (Note 23)
Shareholders' equity (deficit)
Common stock, $0.001 par value, 200,000,000 shares authorized; 99,299,757 and 94,885,028 shares issued and outstanding as of August 31, 2026 and May 31, 2026, respectively (Note 14)
Shares to be issued
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive gain (loss)
Total shareholders' equity (deficit)
Total liabilities and shareholders' equity (deficit)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support